Medulloblastoma drugs in development: Current leads, trials and drawbacks
Autor: | Jiachen Wen, M. Kyle Hadden |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
Surgical resection medicine.medical_specialty Poor prognosis medicine.medical_treatment Malignant brain tumor Antineoplastic Agents 01 natural sciences Article 03 medical and health sciences Cell Line Tumor Internal medicine Drug Discovery medicine Animals Humans Cerebellar Neoplasms Protein Kinase Inhibitors 030304 developmental biology Pharmacology Medulloblastoma 0303 health sciences Chemotherapy 010405 organic chemistry Chemistry Organic Chemistry Wnt signaling pathway General Medicine medicine.disease 0104 chemical sciences Tumor recurrence Radiation therapy |
Zdroj: | Eur J Med Chem |
ISSN: | 0223-5234 |
Popis: | Medulloblastoma (MB) is the most common malignant brain tumor in children. Current treatment for MB includes surgical resection, radiotherapy and chemotherapy. Despite significant progress in its management, a portion of children relapse and tumor recurrence carries a poor prognosis. Based on their molecular and clinical characteristics, MB patients are clinically classified into four groups: Wnt, Hh, Group 3, and Group 4. With our increased understanding of relevant molecular pathways disrupted in MB, the development of targeted therapies for MB has also increased. Targeted drugs have shown unique privileges over traditional cytotoxic therapies in balancing efficacy and toxicity, with many of them approved and widely used clinically. The aim of this review is to present the recent progress on targeted chemotherapies for the treatment of all classes of MB. |
Databáze: | OpenAIRE |
Externí odkaz: |